Balyasny Asset Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-1,069,013
| Closed | -$56.1M | – | 1885 |
|
|
2020
Q3 | $56.1M | Buy |
+1,069,013
| New | +$44.3M | 0.41% | 38 |
|
|
2020
Q2 | – | Sell |
-91,044
| Closed | -$2.48M | – | 1628 |
|
|
2020
Q1 | $2.48M | Buy |
91,044
+19,017
| +26% | +$529K | 0.03% | 576 |
|
|
2019
Q4 | $1.42M | Buy |
+72,027
| New | +$1.15M | 0.01% | 827 |
|
|
2019
Q2 | – | Sell |
-67,881
| Closed | -$986K | – | 1834 |
|
|
2019
Q1 | $986K | Sell |
67,881
-8,435
| -11% | -$108K | 0.01% | 1024 |
|
|
2018
Q4 | $843K | Sell |
76,316
-382,671
| -83% | -$5.33M | 0.01% | 948 |
|
|
2018
Q3 | $12.1M | Buy |
458,987
+137,549
| +43% | +$3.72M | 0.05% | 430 |
|
|
2018
Q2 | $6.57M | Buy |
321,438
+197,938
| +160% | +$4.25M | 0.03% | 605 |
|
|
2018
Q1 | $2.24M | Buy |
+123,500
| New | +$2.06M | 0.01% | 962 |
|
|
2015
Q2 | – | Sell |
-121,790
| Closed | -$1.85M | – | 1408 |
|
|
2015
Q1 | $1.85M | Buy |
+121,790
| New | +$1.58M | 0.02% | 640 |
|
|
2013
Q4 | – | Sell |
-60,318
| Closed | -$868K | – | 689 |
|
|
2013
Q3 | $868K | Buy |
+60,318
| New | +$923K | 0.01% | 535 |
|
Balyasny Asset Management's MNTA Position: Q4 2020 in Review
Balyasny Asset Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 1,069,013 shares — an estimated $56.1M sold.
Balyasny Asset Management first reported a position in MNTA in Q3 2013 and held it in 10 quarters. The position peaked at $56.1M in Q3 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- Balyasny Asset Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- Balyasny Asset Management sold 1,069,013 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $56.1M.
- Balyasny Asset Management first reported a position in Momenta Pharmaceuticals, Inc. in Q3 2013 and held it in 10 quarters.
- Balyasny Asset Management's Momenta Pharmaceuticals, Inc. position peaked at $56.1M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on Balyasny Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.